Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910306 · ClinicalTrials.gov registry record · NA
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
A NA study of Recurrent Glioblastoma and Recurrent Gliomas, sponsored by Alpha Tau Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06910306 is a NA study of Recurrent Glioblastoma and Recurrent Gliomas that is actively recruiting participants, run by Alpha Tau Medical. The registered enrollment target is 10 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06910306, a NA study of Recurrent Glioblastoma and Recurrent Gliomas, is actively recruiting participants, sponsored by Alpha Tau Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
Conditions Studied
Interventions
- DEVICE Device :DaRT seeds
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06910306
The ClinicalTrials.gov registry entry for NCT06910306 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (86% lower). The listed sponsor is Alpha Tau Medical, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Device :DaRT seeds is the first listed.
NCT06910306 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06910306 about?
NCT06910306 is a clinical study titled "A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma". A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
What is the current status of trial NCT06910306?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-10-01. Estimated completion is 2026-12-01.
What conditions does trial NCT06910306 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent Gliomas.
What interventions are being tested in trial NCT06910306?
The interventions under investigation include: Device :DaRT seeds (DEVICE).
Who is sponsoring clinical trial NCT06910306?
This trial is sponsored by Alpha Tau Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06910306 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
RECRUITING · NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
RECRUITING · NA
-
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
ACTIVE NOT RECRUITING · NA
-
Mathematical Model-Adapted Radiation In Glioblastoma
COMPLETED · NA
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.